VivoSeq
Gastroenterology

Constipation

115

Pipeline Programs↗

25

Active Trials↗

45

Companies Involved↗

Constipation is a highly competitive landscape with 115 programs across 45 companies. The most active players are Theravance Biopharma, NGM Biopharmaceuticals, Inc, Anji Pharma. 29 therapies are approved with 31 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

73/100

Pipeline Velocity

27/100

Mech. Concentration

17/100

Completion Rate

79/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Theravance Biopharma

1 program

Phase 2N

NGM Biopharmaceuticals, Inc

1 program

Phase 2A

Anji Pharma

1 program

Phase 2B

BioGaia Pharma AB

1 program

Phase 2S

S.L.A. Pharma AG

1 program

Phase 2K

Kissei Pharmaceutical Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

99%

Small molecule

147 of 149 classified programs — the dominant modality here.

1%ALL OTHERSPeptide21%

Small molecule leads; the ring shows all 149 classified programs, each share of the total. Modality classified for 99% of 155 pipeline programs.

Analysis

Trial Status

209

clinical trials

Completed130 · 62%
Terminated26 · 12%
Unknown status20 · 10%
Recruiting16 · 8%
Withdrawn7 · 3%
Not yet recruiting6 · 3%
Other4 · 2%

Clinical Trials

Trial Activity

209 trials

Clinical Study of Acupoint Application on Relieving qi Deficiency and Constipation in Patients Undergoing Chemotherapy
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07276932·106 enrolled
Tenapanor in Synucleinopathy-Related Constipation
Recruiting·—·Phase 2·NCT06460038·30 enrolled
Levofloxacin in the Treatment of Chronic Functional Constipation Associated With PIB(Peristaltic Contraction-Inhibiting Bacterium) Infection
Recruiting·—·N/A·NCT06571097·50 enrolled
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
Recruiting·AArdelyx·Phase 3·NCT07382167·692 enrolled
Evaluation of the Efficacy and Safety of Fecal Microbiota Transplantation for Constipation in Parkinson's Disease
Recruiting·SShanghai Zhongshan Hospital·N/A·NCT06388863·76 enrolled
Effect of Lactobacillus DSM17938+ on Functional Constipation and Intestinal Flora in Pregnant Women
Recruiting·PPeking Union Medical College Hospital·N/A·NCT06802042·40 enrolled
Effects of Probiotics (BioKid LR - Contains Nine Different Species of Probiotics Bacteria Including L. Reuteri) in Children With Functional Constipation
Recruiting·—·Phase 4·NCT06959758·80 enrolled
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
Recruiting·BBioDelivery Sciences International·N/A·NCT03720613·34,532 enrolled
Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation
Recruiting·XXijing Hospital of Digestive Diseases·N/A·NCT06221722·150 enrolled
Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation
Recruiting·TThird Military Medical University·Phase 3·NCT07277907·346 enrolled
A Single Arm Pilot Study of the Chinese Herbal Medicine Formula (SCD-2101) for the Functional Constipation in the Elderly
Recruiting·HHong Kong Baptist University·N/A·NCT06534996·14 enrolled
Assessing Tenapanor as a Treatment of CF-related Constipation.
Recruiting·MMassachusetts General Hospital·Phase 3·NCT06810167·25 enrolled
Prevention of Opioid-induced Constipation in Patients With Advanced Cancer
Recruiting·AAmsterdam UMC, location VUmc·Phase 4·NCT05216328·330 enrolled
Naldemedine in Clinical Practice in Cancer Patients With Opioid Induced CONstipation: Clinical Outcomes and Patient Experience
Recruiting·PProfessor Monique A. H. Steegers·N/A·NCT07231796·100 enrolled
Anorectal Manometery in Pediatric Chronic Refractory Constipation
Recruiting·—·Phase 1/2·NCT06543979·60 enrolled
Page 1 of 14

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)